Biosimilars Indian pharmaceutical companies focusing on US generics are building specialty generics pipelines. Price erosion due to increased competition in the USA has hastened Indian drug firms' push towards specialty medicines. The complexity being tapped is the active pharmaceutical ingredient (API) or formulation routes of delivery, a complex dosage form, or where the approval pathway has changed, reports The Pharma Letter’s India correspondent. 30 June 2021